MEINIAN ONEHEALTH HEALTHCARE HOLDINGS CO., LTD.

Ratings Meinian Onehealth Healthcare Holdings Co., Ltd.

Equities

002044

CNE000001LV7

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
3.98 ^CNY	-3.86%		-6.79%	-33.78%

Apr. 29	Meinian Onehealth Healthcare Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Meinian Onehealth Healthcare Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's profit outlook over the next few years is a strong asset.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
MEINIAN ONEHEALTH HEALTHCARE HOLDINGS CO., LTD.	-33.78%	2.22B	C-
HCA HEALTHCARE, INC.	+24.74%	88.24B	C+
CVS HEALTH CORPORATION	-23.68%	76.2B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.76%	26.63B	C+
FRESENIUS SE & CO. KGAA	+8.16%	18.14B	A-
LABCORP HOLDINGS INC.	-12.82%	16.69B	B
QUEST DIAGNOSTICS INCORPORATED	+3.82%	15.85B	A-
NATERA, INC.	+75.27%	13.61B	C-
TENET HEALTHCARE CORPORATION	+78.01%	13.24B	C+
DAVITA INC.	+38.13%	12.72B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes